DNA Laboratories Sdn Bhd (DNA LAB) is a leading provider of genetic screening and molecular diagnostic services and products in Malaysia. Set up in 2007, the company is currently headquartered in UKM-MTDC Technology Centre in Bangi, Malaysia.

Proud to be the leading molecular diagnostic laboratory for fetal medicine, women’s health and oncology, we specializes in developing DNA test assays and molecular diagnostic kits to provide a dependable, accurate and rapid identification of genetic abnormalities associated with genetic diseases and cancer. DNA LAB provides reference functions in screening and diagnostic services for all Obstetricians, Gynecologists, Pediatrics, GP clinics, Medical Centres and major hospitals throughout Malaysia.

DNA LAB possesses the capabilities to research, design, develop and manufacture in vitro Molecular Diagnostic Kits (MDK) with specific biomarkers for the detection of both genetic inherited diseases of family inherited predisposition genes and infectious agents.

We also boast a specialized, well-equipped laboratory with a team of dedicated and friendly staff and pride ourselves in providing the best possible services.

HPV XpressMatrix

DNA LAB is the only biotechnology company in Malaysia that manufactures its own HPV diagnostic kit, called HPV XpressMatrix™, with full in-house testing services mainly for women in the reproductive age. HPV XpressMatrix™ is designed to detect the most common 21 subtypes of Human Papillomavirus (HPV) which is the leading cause of cervical cancer, where more than 95% of cervical cancer patients were detected with HPV infection.

Our diagnostic product portfolio also consists of ChromosomeCheck™ for the detection of Down’s syndrome and ThalaCheck® for the detection of thalassaemia, mainly performed by using in-house kits.

DNA LAB’s capabilities in designing molecular diagnostic assays is aimed at contributing to the better management of family inherited diseases and cancer cases. Early stage screening for mutations and diseases by using molecular biomarkers will significantly improve the quality of medical care people can receive and people’s lives and will play an important part in the future. The eventual savings on health care and medical costs will greatly offset the costs of molecular diagnosis and screening.